Apellis Pharmaceuticals Inc. delivered an oral presentation at the ARVO Annual Meeting in New Orleans announcing their post hoc analyses from the Phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy (GA).
RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.
Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.
Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.
New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).
Researchers conducted clinical imaging and histopathologic studies to gain a better understanding of geographic atrophy (GA) in 3 siblings.
Imaging biomarkers are useful to determine the degree of EZ attenuation in the fovea.
Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.
Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.
A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
